Evolution of myeloid-mediated immunotherapy resistance in prostate cancer

10.1038/s41586-024-08290-3

Affiliations
Aram Lyu, Zenghua Fan, Matthew Clark, Averey Lea, Diamond Luong, Ali Setayesh, Alec Starzinski, Rachel Wolters, Marcel Arias-Badia, Kate Allaire, Kai Wu, Vibha Gurunathan, Laura Valderrábano, Xiao X Wei, Richard A Miller, Eliezer M Van Allen, Lawrence Fong

DOI: 10.1038/s41586-024-08290-3

Abstract
Patients with advanced metastatic castration-resistant prostate cancer (mCRPC) are refractory to immune checkpoint inhibitors (ICIs)

Keywords
mCRPC，CD3，ICIs

관련 제품

카탈로그 번호	제품명	설명	타겟
HY057507	CD3	Anti-Human CD3 Antibody (SP34) [SP34] (HY057507) is a mouse monoclonal antibody detecting T-cell surface glycoprotein CD3 epsilon chain in FCM. Suitable for Human. Highlights ●Flow Cytometry — Validated for flow cytometry applications.	T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain

재조합 단백질

항체

어세이 키트

Evolution of myeloid-mediated immunotherapy resistance in prostate cancer

빠른 접근

문의하기